Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Completed · Phase 2 · NCT03861702
Conditions: Locally Advanced Pancreatic Carcinoma(LAPC)
At a glance
- Research payments reported, 2025
- $226,808
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 28
About the trial
- Sponsor
- Nelson Yee (with Ipsen)
- Tested
- FOLFOX regimen (drug), Liposomal Irinotecan (drug)
- Dates
- Started 2020-09-02; completion 2024-09-27
- Results posted
- Yes
This is a phase II, single-arm, open-label, clinical study to investigate the efficacy and tolerability of a combination of liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced pancreatic carcinoma (LAPC).
From ClinicalTrials.gov, last updated 2025-04-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $226,808 in research payments for this study in 2025 (4 payments).
Products named: Onivyde
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Pennsylvania State University College of Medicine $113,404
- Hoosier Cancer Research Network $113,404
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.